Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Deal Size: $1,150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.